These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 39071106)

  • 1. Biosimilar underutilization alone does not foretell a broken biologics market.
    LaMountain F; Beinfeld MT; Wong W; Kim E; Chambers JD
    Health Aff Sch; 2024 Jul; 2(7):qxae090. PubMed ID: 39071106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices Decrease.
    Beinfeld MT; LaMountain F; Wong W; Kim E; Chambers JD
    Health Aff (Millwood); 2024 Sep; 43(9):1290-1295. PubMed ID: 39226499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
    Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
    Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
    [No Abstract]   [Full Text] [Related]  

  • 4. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
    Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
    BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
    Kim Y; Kwon HY; Godman B; Moorkens E; Simoens S; Bae S
    Front Pharmacol; 2020; 11():970. PubMed ID: 32733238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.
    Chen HH; Yemeke T; Ozawa S
    PLoS One; 2024; 19(6):e0304851. PubMed ID: 38843282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.
    Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
    BioDrugs; 2019 Jun; 33(3):285-297. PubMed ID: 30945207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.
    Bhardwaja B; Klocke S; Ekinci E; Jackson A; Kono S; Olson KL
    BioDrugs; 2022 Jan; 36(1):1-11. PubMed ID: 34817847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar Competition and Payments in Medicare: The Case of Trastuzumab.
    Horn DM; Alpert AE; Duggan MG; Garcia NA; Jacobson M
    JCO Oncol Pract; 2023 Apr; 19(4):e476-e483. PubMed ID: 36638330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar competition: Early learning.
    Frank RG; Shahzad M; Kesselheim AS; Feldman W
    Health Econ; 2022 Apr; 31(4):647-663. PubMed ID: 35023225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Expiry of Humira
    Moorkens E; Godman B; Huys I; Hoxha I; Malaj A; Keuerleber S; Stockinger S; Mörtenhuber S; Dimitrova M; Tachkov K; Vončina L; Palčevski VV; Achniotou G; Slabý J; Popelková L; Kohoutová K; Bartels D; Laius O; Martikainen JE; Selke GW; Kourafalos V; Magnússon E; Einarsdóttir R; Adams R; Joppi R; Allocati E; Jakupi A; Viksna A; Greičiūtė-Kuprijanov I; Vella Bonanno P; Suttorp V; Melien Ø; Plisko R; Mardare I; Meshkov D; Novakovic T; Fürst J; Zara C; Marković-Peković V; Grubiša N; Befrits G; Puckett R; Vulto AG
    Front Pharmacol; 2020; 11():591134. PubMed ID: 33519450
    [No Abstract]   [Full Text] [Related]  

  • 16. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting.
    Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
    BioDrugs; 2019 Jun; 33(3):299-306. PubMed ID: 30945206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim.
    McBride A; Wang W; Campbell K; Balu S; MacDonald K; Abraham I
    J Med Econ; 2020 Aug; 23(8):856-863. PubMed ID: 32323582
    [No Abstract]   [Full Text] [Related]  

  • 18. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
    Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
    Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023.
    Wu Q; Wang Z; Fu Y; Luo R; Sun J
    Glob Health Res Policy; 2024 Oct; 9(1):42. PubMed ID: 39367503
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.